Home > Specialists > Urology > Dr. Dingwei Ye (叶定伟)
Specialty & Clinical Focus:
Urologic oncology specialist at Fudan University Shanghai Cancer Center in Shanghai, China, with a clinical focus on prostate, bladder, kidney, testicular, adrenal, penile and retroperitoneal tumors, minimally invasive and Da Vinci robotic surgery, and multidisciplinary cancer treatment.
Professional Title & Qualifications:
Chief Physician
Professor
M.D.
Ph.D.
Doctoral Supervisor
Hospital & Department：
Fudan University Shanghai Cancer Center – Department of Urology
(address: No. 270 Dong'an Road, Xuhui District, Shanghai, 200032)
Dr. Dingwei Ye (叶定伟) - Urologic Oncology Specialist
Personal Biography
Professor Dingwei Ye is Vice President of Fudan University Shanghai Cancer Center (FUSCC), Academic Leader of its Department of Urology, Chief Expert of the Multidisciplinary Team for Urologic Tumors, and Director of both the Shanghai Urological Cancer Institute and the Fudan University Prostate Cancer Institute.
His clinical work focuses on the surgical and comprehensive treatment of genitourinary tumors, and he performs nearly 1,000 radical surgeries annually. After training at the University of Texas MD Anderson Cancer Center, he helped advance minimally invasive surgical techniques and comprehensive treatment approaches for urologic cancers in China. He also leads international and domestic multicenter clinical research in urologic oncology.
Why Consider Dr. Dingwei Ye for Urologic Oncology Care?
International patients with complex prostate, kidney, bladder or other genitourinary tumors may consider Dr. Dingwei Ye when seeking a specialist opinion from Fudan University Shanghai Cancer Center. His institutional leadership, MD Anderson training and experience with minimally invasive, Da Vinci robotic and multidisciplinary approaches are particularly relevant when a case may involve surgery, systemic therapy or coordination across specialties.
A remote specialist review allows Dr. Ye's team to examine pathology, imaging, prior treatment history and the patient's key questions before travel. The resulting opinion and recommendations can help patients understand the proposed next steps, identify records that may still be needed and decide whether to pursue an in-person pathway in Shanghai. His leadership of more than 50 multicenter clinical trials further connects his clinical practice with ongoing research in urologic oncology.
Pre-Travel Case Review & Specialist Liaison
Before arranging travel to Shanghai, MedBridgeNZ coordinates a structured pre-travel case review pathway with Dr. Ye's hospital team. With your authorization, we help organize and translate relevant medical records, transfer them securely to the hospital and coordinate the questions you want the specialist to address. The hospital team will review the submitted records and provide its clinical opinion, recommendations and responses through the arranged pathway.
If you decide to pursue care in China, MedBridgeNZ can then coordinate appointment requests, medical invitation or visa-document support, travel planning, accommodation arrangements and non-clinical bilingual administrative support. This sequence gives you specialist feedback and a clearer view of the proposed next steps before making travel arrangements.
Disclaimer: MedBridgeNZ is a medical concierge provider serving a global client base. We assist with logistical coordination and facilitate access to healthcare professionals. MedBridgeNZ does not provide medical advice, diagnoses, or treatments.Any clinical feedback, treatment planning or suitability discussion remains with the relevant hospital or licensed specialist.
Secure a Remote Case Review with
Dr. Dingwei Ye
Areas of Expertise
Diagnosis and treatment of benign and malignant tumors of the genitourinary system (prostate cancer, bladder cancer, kidney cancer, testicular cancer, adrenal tumors, penile cancer, and retroperitoneal tumors)
Minimally invasive surgery, including Da Vinci robotic surgery
Comprehensive multidisciplinary treatment, including chemotherapy, radiotherapy, immunotherapy, interventional therapy, and hormonal therapy for urologic cancers
Early diagnosis and individualized treatment of prostate cancer
Verified Client Satisfaction Metrics
⭐⭐⭐⭐⭐ 5.0/5.0 Overall Rating
* Treatment Pathway Satisfaction:
5.0/5.0
* Communication & Professionalism:
5.0/5.0
* High demand: Chosen online for specialist liaison and case reviews by over:
20,000 clients
(Source: These third-party platform indicators are provided for general reference only. They may change over time and should not be interpreted as a guarantee of diagnosis, treatment suitability, appointment availability, or individual clinical outcome.)
Work Experience
Vice President, Fudan University Shanghai Cancer Center
Director, Department of Urology, Fudan University Shanghai Cancer Center
Director, Shanghai Urological Cancer Institute
Director, Fudan University Prostate Cancer Institute
Principal Investigator, leading over 50 international and domestic multi-center clinical trials and research projects
Education & Training
Specialized training, University of Texas MD Anderson Cancer Center
Awards & Honors
First Prize, Shanghai Science and Technology Progress Award (Principal Achiever, 2 times)
First Prize, Science and Technology Achievement Award of the Ministry of Education (Principal Achiever)
First Prize, Shanghai Medical Science and Technology Award (Principal Achiever)
National Science and Technology Progress Award (First Prize, 3rd Achiever)
Wu Jieping Urology Award
State Council Special Allowance Expert
Shanghai Leading Talent & Shanghai Medical Leading Talent
Outstanding Young and Middle-aged Expert with Outstanding Contributions (National Health Commission)
Academic & Professional Memberships
Chairman, Genitourinary Cancer Committee of the China Anti-Cancer Association (CACA)
Chairman, Prostate Cancer Committee of the Chinese Society of Clinical Oncology (CSCO)
Vice Chairman, CSCO Urothelial Carcinoma Committee
Vice Chairman, CSCO Renal Cancer Committee
Vice Chairman, CSCO Immunotherapy Committee
Chairman, Urological Cancer Cooperation Group (UCOG) of Chinese Cancer Hospitals
Executive Member, Asian Pacific Prostate Society (APPS)
Member, Expert Committee for NCCN Asia Consensus Guidelines (Prostate, Kidney, and Bladder Cancer)
Vice President, Shanghai Medical Doctor Association - Urologist Branch
Research & Publications
Presided over more than 50 national and provincial-level scientific research funds
Published over 540 academic papers as first or corresponding author (including 290+ SCI papers) in journals such as Nature Genetics, Journal of Clinical Oncology (JCO), European Urology (EU), and Clinical Cancer Research (CCR)
Editor-in-chief or translator of 9 medical monographs
Holder of 19 invention and utility model patents
Selected Peer-Reviewed Publications
Selected peer-reviewed publications by Dr. Dingwei Ye:
Gu W, Ye D, et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer (CHART). Lancet Oncol. 2022;23(10):1249–1260. PMID: 36075260.
Zhu Y, Ye D, et al. Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol. 2021;18(5):282–301. PMID: 33692499.
Wu J, Ye D, et al. Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection. Mol Cancer. 2024;23(1):57. PMID: 38504268.
*The doctor’s information is sourced from the hospital’s official website or provided directly by the doctor. Due to update cycles, there may be occasional delays in reflecting the most recent changes.
Frequently Asked Questions (FAQs)
Can Dr. Dingwei Ye review my urologic cancer case before I travel to China?
Dr. Ye’s clinical focus includes prostate, bladder, kidney, testicular, adrenal, penile and retroperitoneal tumors. Through the coordinated remote specialist-review pathway, his hospital team will review the medical records you submit and provide its opinion, recommendations and responses to your questions. MedBridgeNZ helps organize the records, translation, client-authorized document transfer and communication. This pre-travel step can help you understand the proposed next steps and identify any additional records requested by the hospital before deciding whether to pursue an in-person pathway in Shanghai.
How can international patients request an appointment with Dr. Dingwei Ye in Shanghai?
MedBridgeNZ coordinates the appointment request and communication with Fudan University Shanghai Cancer Center, helps prepare and translate medical records, and can arrange non-clinical bilingual administrative support for the hospital visit. Once the hospital confirms the appointment details, we help organize medical invitation or visa-document support, travel planning and accommodation. Appointment timing and onsite arrangements follow the hospital’s scheduling process, while our role is to keep the administrative pathway organized for international patients.
What support is available if I travel to China after the remote specialist review?
After receiving Dr. Ye’s hospital team’s opinion and recommendations, you can decide whether to pursue an in-person pathway in Shanghai. If you proceed, MedBridgeNZ coordinates appointment requests, medical invitation or visa-document support, travel and accommodation planning, translation coordination and non-clinical bilingual administrative support. Hospital admission, diagnostic testing and treatment arrangements are confirmed by Fudan University Shanghai Cancer Center through its clinical and scheduling process. We also help keep hospital communication and travel logistics aligned with the proposed timeline.
Flexible Ways to Connect with the Specialist
We understand that every client’s situation is unique. Beyond the Remote Written Review, we offer a range of flexible ways to access specialist insights:
-
Remote Video Liaison: For a more personal interaction, we can arrange a live video session, allowing you to discuss your case directly with the specialist with the help of our professional medical translators.
-
On-Site Proxy Liaison: If you cannot travel, our dedicated bilingual team can visit the hospital in person on your behalf. We will present your translated medical records to the specialist, facilitate your inquiries, and provide you with a comprehensive translated report of the doctor’s findings.
-
In-Person Appointment Booking: If you are planning to travel to China for treatment, we manage the complex hospital registration and appointment process, ensuring you have confirmed access to your chosen specialist upon arrival.
How MedBridgeNZ Helps You:
MedBridgeNZ is a medical concierge and logistics coordination provider for international patients seeking specialist-care pathways in China. We coordinate appointment requests, medical-record preparation, translation, client-authorized document transfer, medical invitation or visa-document support, travel planning, accommodation arrangements and non-clinical bilingual administrative support. MedBridgeNZ does not provide medical advice, diagnosis or treatment; these are provided by independent hospitals and licensed specialists. Hospital, specialist and other third-party medical or travel costs remain separate unless expressly stated in writing.